Skip to main content Accessibility help
×
Home

Concurrent chemoradiotherapy with carboplatin and uracil–ftegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx

  • T Taguchi (a1), M Tsukuda (a1), Y Mikami (a1), C Horiuchi (a1), J-I Ishitoya (a2) and H Katori (a2)...

Abstract

This study aimed to evaluate the efficacy and toxicity of concurrent chemoradiotherapy as a primary treatment modality for larynx preservation in patients with stage two squamous cell carcinoma (SCC) of the glottic larynx. Between February 2000 and August 2003, a total of 20 patients received concurrent chemoradiotherapy. Carboplatin was given intravenously once a week during the period of radiotherapy. The weekly carboplatin dose was based on the area under the curve 1 to 1.25. Uracil–ftegafur (UFT) was given in a daily oral dose of 300 mg as tegafur. Radiotherapy was delivered five days a week using a once-daily fractionation of 2.0 Gray (Gy), to a total dose of 66–72 Gy. The three-year overall survival rate with larynx preservation was 100 per cent.

Concurrent chemoradiotherapy with carboplatin and UFT for stage two SCC of the glottic larynx was safe and effective in improving local control with larynx preservation.

Copyright

Corresponding author

Address for correspondence: Dr Takahide Taguchi, Department of Otorhinolaryngology, Yokohama City University School of Medicine, 3–9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan. Fax:  + 81 45 783 2580 E-mail: ttaguchi@yokohama-cu.ac.jp

Keywords

Concurrent chemoradiotherapy with carboplatin and uracil–ftegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx

  • T Taguchi (a1), M Tsukuda (a1), Y Mikami (a1), C Horiuchi (a1), J-I Ishitoya (a2) and H Katori (a2)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed